Tvardi Therapeutics’ shares jumped this week after Phase I data for TTI-109 showed improved tolerability alongside target engagement and articulated support plans for mid-stage development. The update is a positive clinical signal that can de-risk the program modestly and drive near-term sentiment toward the stock.
Tvardi Therapeutics’ shares jumped this week after Phase I data for TTI-109 showed improved tolerability alongside target engagement and articulated support plans for mid-stage development. The update is a positive clinical signal that can de-risk the program modestly and drive near-term sentiment toward the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
